Supplementary Table 1. Demographic, clinical and MRI baseline characteristics for the per protocol (PP) population by treatment arm

	Placebo				Neuroaspis® plp10				
	N	**mean±SD/ median [IQR]/ N (%)**	**min**	**max**	**N**	**mean±SD/ median [IQR]/ N (%)**	**min**	**max**	**p-value**
Age	20	38.1±6.84	26	55	19	40.16±8.41	28	55	0.384
Sex (female)	20	11 (55)	-	-	19	12 (63.16)	-	-	0.605
Years of diagnosis	20	11.15±7.31	2	28	19	10.84±6.08	4	26	0.833
Weight (kg)	20	69.6±15.73	48	105	19	69.32±12.98	46	100	0.978
Height (cm)	20	167.85±7.8	155	186	19	168±8.96	155	183	0.933
EDSS score visit 1 (normalization phase)	20	2.5 [1.5-3.5]	1	5	19	2 [1.5-3.5]	1	4	0.663
EDSS score visit 2 (baseline)	20	2.5 [1.5-3.5]	1	5	19	2 [1.5-3.5]	1	4	0.555
Annualized relapse rate (estimated from normalization phase)	20	0.3±0.74	0	2.23	19	0±0	0	0	0.083
Relapses at normalization phase	20				19				
0		17 (85)	-	-		19 (100)	-	-	0.231*
1		3 (15)	-	-		0 (0)	-	-	
Total number of T1-enhancing lesions	19	0.21±0.54	0	2	19	0.42±0.84	0	3	0.559
T1-enhancing lesion volume (cubic mm)	19	20.53±48.84	0	142	19	58.53±150.04	0	589	0.609
T2-hyperintense lesion volume (cubic mm)	20	5369.45±4524.28	185	14548	19	4233.95±3121.6	488	10119	0.613

Abbreviations: EDSS: Expanded Disability Status Scale (range of scores, 0 to 10, with higher scores indicating more severe disease); IQR: interquartile range; SD: standard deviation; ITT, intention to treat
Percentages may not sum to 100, because of rounding
* Fisher's exact test

Supplementary Table 2. Primary Endpoint as Determined by Clinical Results for the per protocol (PP) population*

	N	Relapses in 2 years	ARR (95% CI)	min	max
Placebo	20	27	0.68 (0.45, 0.99)	0	1.54
Neuroaspis® plp10	19	0	0.00 (0.00, 0.10)	0	0.00

* ARR, annualized relapse rate; CI, confidence interval; IRR, incidence rate ratio; SD, standard deviation.
** Adjusted for: Age, sex, years of diagnosis, baseline EDSS, relapses during normalization.

Supplementary Table 3. Secondary Endpoint as Determined by Magnetic Resonance Imaging (MRI) Evaluation for the per protocol (PP) population*

Analysis	IRR (95% CI)	p-value
Number of T1-enhancing lesions (month 30)	0.29 (0.08, 1.00)	0.05
New/enlarging T2-hyperintense lesions at month 30 vs baseline	0.29 (0.20, 0.41)	<0.0001

Abbreviations: IRR, Incidence rate ratio; CI, confidence interval
* All analyses adjusted for: Age, sex, years of diagnosis, baseline EDSS, relapses during normalization.

Supplement Figure 1. Secondary endpoint, Expanded Disability Status Scale (EDSS) data analyses for the per-protocol (PP) population



Kaplan–Meier Plots of the Time to Sustained Progression of Disability among Patients Receiving Neuroaspis® plp10 as Compared with Placebo for the PP population. The cumulative probability of progression was 0% in the Neuroaspis® plp10 and 55% in the placebo group.